These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30315613)

  • 1. Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.
    Satoh E; Sasaki Y; Ohkuma R; Takahashi T; Kubota Y; Ishida H; Hamada K; Kiuchi Y; Tsunoda T
    Cancer Sci; 2018 Dec; 109(12):3896-3901. PubMed ID: 30315613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan.
    Okabe A; Hayashi H; Maeda H
    Curr Oncol; 2023 Feb; 30(2):1776-1783. PubMed ID: 36826098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
    Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
    BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
    Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
    J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
    Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
    Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
    Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
    JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficiency of oncologic treatments for solid tumours in Spain].
    Oyagüez I; Frías C; Seguí MÁ; Gómez-Barrera M; Casado MÁ; Queralt Gorgas M
    Farm Hosp; 2013; 37(3):240-59. PubMed ID: 23789801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy.
    Shibata S; Matsushita M; Saito Y; Suzuki T
    Ther Innov Regul Sci; 2018 Nov; 52(6):718-723. PubMed ID: 29714569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
    Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
    Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
    Pinto A; Naci H; Neez E; Mossialos E
    Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An expanded portfolio of survival metrics for assessing anticancer agents.
    Karweit J; Kotapati S; Wagner S; Shaw JW; Wolfe SW; Abernethy AP
    Am J Manag Care; 2017 Jan; 23(1):54-61. PubMed ID: 28141932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 14. Progression-free survival in oncology: Caveat emptor!
    Bergmann TK; Christensen MMH; Henriksen DP; Haastrup MB; Damkier P
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):240-244. PubMed ID: 30417586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
    Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
    Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.
    Ling K; Qin H; Feng Y; Che H; Ding J; Li W
    Front Public Health; 2022; 10():1062736. PubMed ID: 36504948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
    Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
    Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
    Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
    Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.